Shopping Cart
Remove All
Your shopping cart is currently empty
Brazikumab (Synonyms: MEDI2070, MEDI 2070, AMG139, AMG 139)
Catalog No. T76934 Copy Product Info
🥰Excellent
Brazikumab (AMG 139) is a humanized antibody targeting IL-23 by binding to the P19 subunit. It is a selective IL23p19 antagonist and can be used in Crohn's disease research.
Brazikumab
Copy Product Info🥰Excellent
Catalog No. T76934
Synonyms MEDI2070, MEDI 2070, AMG139, AMG 139
Brazikumab (AMG 139) is a humanized antibody targeting IL-23 by binding to the P19 subunit. It is a selective IL23p19 antagonist and can be used in Crohn's disease research.
Brazikumab
Cas No. 1610353-18-8
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $197 | In Stock | In Stock | |
| 5 mg | $516 | In Stock | In Stock | |
| 10 mg | $828 | - | In Stock | |
| 25 mg | $1,230 | - | In Stock | |
| 50 mg | $1,650 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:98% (SDS-PAGE); 97.7% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Brazikumab (AMG 139) is a humanized antibody targeting IL-23 by binding to the P19 subunit. It is a selective IL23p19 antagonist and can be used in Crohn's disease research. |
| Targets&IC50 | IL-23:0.138 nM (Kd) |
| In vitro | Brazikumab is a human IgG2 monoclonal antibody that binds to the p19 subunit with high affinity and has a KD of 0.138 nM against human IL-23. Brazikumab inhibits the binding of recombinant and natural IL-23 to receptors that are stably expressed in COS cells with IC50 of 188 and 284 pM, respectively. Brazikumab inhibits in vitro production of IFN-γ in NK cells stimulated by human natural or recombinant IL-23 (bound to IL-18) with IC50 of 238 and 93 pM, respectively. [1] |
| Synonyms | MEDI2070, MEDI 2070, AMG139, AMG 139 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | IL-23 |
| Molecular Weight | 145.78 kDa |
| Cas No. | 1610353-18-8 |
| Isotype | IgG2SA |
| Storage | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
Preview
Related Tags: buy Brazikumab | purchase Brazikumab | Brazikumab cost | order Brazikumab | Brazikumab in vitro | Brazikumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.